Mallinckrodt plc to Report Second Quarter Results on May 8, 2014
DUBLIN--(BUSINESS WIRE)--Apr. 21, 2014--
plc (NYSE: MNK) will report second quarter results on Thursday, May 8,
2014. The company will hold a conference call for investors from
7:30-8:00am, U.S. Eastern Time. Shortly after the earnings call, the
company will hold a separate “live” fireside chat question and answer
session for investors at the St. Regis New York, 2 East 55th
Street at 5th Avenue in New York City, which will also be
available by conference call.
Those wishing to attend the fireside chat may arrive at the St. Regis at
7:30am and proceed to the St. Regis Roof Meeting room, where questions
will be taken both live and by phone beginning at 8:15am.
The calls can be accessed in three ways.
At the Mallinckrodt website: http://mallinckrodt.com/investor_relations.aspx
By telephone: For both “listen-only” participants and those who wish
to take part in the question-and-answer portion of the second session,
the telephone dial-in number in the U.S. (877) 359-9508. For
participants outside the U.S., the dial-in number is (224) 357-2393.
The conference I.D. (access number) for the earnings call at 7:30am is
30870215 and the I.D. for the Fireside Chat is 32627753
Through an audio replay: A replay of the call will be available by 4pm
U.S. Eastern Time on May 8, 2014, and ending at 11:59pm/ U.S. Eastern
Time on May 15, 2014. The dial-in number for U.S. participants is
(855) 859-2056. For participants outside the U.S., the replay dial-in
number is (404) 537-3406. The replay conference I.D. for the earnings
call is 30870215 and the conference I.D. to hear the Fireside Chat is
Those who listen to the earnings call or webcast will need to call back
to the same number noted above to participate in the fireside chat.
Please note the two segments have separate conference I.D. numbers.
If you wish to join the live fireside chat at the St. Regis New York,
please RSVP to Investor.Relations@Mallinckrodt.com
to ensure you are registered.
Mallinckrodt is a global specialty pharmaceutical and medical imaging
business that develops, manufactures, markets and distributes specialty
pharmaceutical products and medical imaging agents. The company’s core
strengths include the acquisition and management of highly regulated raw
materials; deep regulatory expertise; and specialized chemistry,
formulation and manufacturing capabilities. The company’s Specialty
Pharmaceuticals segment includes branded and specialty generic drugs and
active pharmaceutical ingredients, and the Global Medical Imaging
segment includes contrast media and nuclear imaging agents. Mallinckrodt
has approximately 5,500 employees worldwide and a commercial presence in
approximately 65 countries. The company’s fiscal 2013 revenue totaled
$2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt plc
Vice President, Investor Relations
Senior Vice President, Communications